These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12427509)

  • 1. Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.
    de Maistre E; Allart C; Lecompte T; Bollaert PE
    Am J Med; 2002 Oct; 113(6):530-2. PubMed ID: 12427509
    [No Abstract]   [Full Text] [Related]  

  • 2. Tinzaparin in long-term treatment of deep venous thrombosis.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Eur J Vasc Endovasc Surg; 2007 Sep; 34(3):353-4. PubMed ID: 17574456
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of Bleeding in Patients on Full-Dose Enoxaparin With Venous Thromboembolism and Selective Serotonin Reuptake Inhibitors.
    Samuel NG; Seifert CF
    Ann Pharmacother; 2017 Mar; 51(3):226-231. PubMed ID: 27834194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
    Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
    Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splenic spontaneous rupture (SSR) and hemoperitoneum associated with low molecular weight heparin: a case report.
    Taccone FS; Starc JM; Sculier JP
    Support Care Cancer; 2003 May; 11(5):336-8. PubMed ID: 12690538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Your patient needs antithrombotics: leg venous thrombosis : how to proceed?].
    MMW Fortschr Med; 2014 Mar; 156(4):28. PubMed ID: 24908764
    [No Abstract]   [Full Text] [Related]  

  • 7. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
    [No Abstract]   [Full Text] [Related]  

  • 8. Tinzaparin: excess mortality in elderly patients with renal failure. Unfractionated heparin is best in this setting.
    Prescrire Int; 2009 Oct; 18(103):216. PubMed ID: 19882795
    [No Abstract]   [Full Text] [Related]  

  • 9. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients.
    Pautas E; Gouin I; Bellot O; Andreux JP; Siguret V
    Drug Saf; 2002; 25(10):725-33. PubMed ID: 12167068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What are the safety measures for use of low-molecular-weight heparins in the treatment of deep venus thrombosis?].
    Fiessinger JN
    Presse Med; 2000 Apr; 29(13):766-8. PubMed ID: 10797834
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of antidepressants plus antithrombotics and bleeding risk: a pharmacovigilance study.
    Montastruc JL; Bura-Rivière A
    Eur J Clin Pharmacol; 2024 Feb; 80(2):283-285. PubMed ID: 38112734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin for treating venous thromboembolism.
    Mahoney MS; Kahn M
    Ann Intern Med; 1999 Jan; 130(1):77-8. PubMed ID: 9890863
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiplatelet, anticoagulant, and thrombolytic drug interactions.
    Iqbal O; Mousa SA
    Methods Mol Med; 2004; 93():9-20. PubMed ID: 14733324
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood.
    Bampalis VG; Khandoga AL; Siess W
    Thromb Haemost; 2010 Dec; 104(6):1272-4. PubMed ID: 20806122
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cancer and deep vein thrombosis].
    Steiner A
    Wien Med Wochenschr; 2005 Jan; 155(1-2):14-6. PubMed ID: 15773738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tinzaparin in the treatment of venous thromboembolism.
    Pineo GF; Hull RD
    Expert Opin Pharmacother; 2003 Dec; 4(12):2355-62. PubMed ID: 14640933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tinzaparin sodium: a low-molecular-weight heparin.
    Neely JL; Carlson SS; Lenhart SE
    Am J Health Syst Pharm; 2002 Aug; 59(15):1426-36. PubMed ID: 12166042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin.
    Wang C; Zhai Z; Yang Y; Cheng Z; Ying K; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH; Davidson BL;
    Clin Respir J; 2016 Sep; 10(5):596-605. PubMed ID: 25619125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.